Overall, 20% (n = 9) of patients had ETP-ALL/LBL immunophenotype, with CD5(−) (44.4%) or CD5(+)weaker (55.6%) expression, co-expressed with CD34(100%), HLA-DR(37.5%), CD13(40%), CD33(80%), and CD15(25%). This evidence concerns the gene CD33 and acute lymphoblastic leukemia.